Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted must obtain authorization.
January 12, 2026, Oricell Therapeutics Holdings Limited ("QrigincellTherapeutics" or "Oricell" or "the Company"), a global leader in innovative tumor immunotherapy, announced todayCompleted a $70 million Series C1 financing roundThis round of financing was led by Beijing Medical and Health Industry Investment Fund, Qiming Venture Partners, and a globally leading healthcare fund. Other investors include an international sovereign fund, NGS (Australian pension fund), Yizhuang State Investment, Licheng Investment, and Ruifeng Capital.
As an innovative pioneer in the field of cell therapy drugs, Qrigincell Therapeutics has always been committed to developing CAR-T cell therapies with global clinical value, and has generated proof-of-concept (POC) clinical data from multiple pipelines. Oricell leverages its self-innovated Ori®Ab antibody screening and engineering platform, Ori®Armoring structural platform, and OnGo(Fast)CMC process expertise to occupy the global CAR-T technology high ground with differentiated pipelines.
Ori-C101, developed by Qrigincell Therapeutics, is an autologous CAR-T drug targeting GPC3 for the treatment of advanced hepatocellular carcinoma (HCC). It has completed Phase I investigator-initiated clinical studies and Phase I registrational clinical trials, and is about to commence pivotal Phase II clinical trials. The available clinical data demonstrate excellent efficacy and safety, and have been presented multiple times at top international academic conferences such as ASCO. This product is expected to become the world’s first approved CAR-T therapy for hepatocellular carcinoma.At the same time, Qrigincell Therapeutics' full platform is giving rise to multiple next-generation multi-target and multi-mechanism CAR-T products. Its innovative secretory CAR-T, OriC902, has achieved breakthrough efficacy in end-stage solid tumor patients. The company’s self-developed dual-target in vivo CAR-T product has initiated exploratory clinical research, validating the technical potential of "off-the-shelf CAR-T" – directly generating CAR-T cells within the patient’s body, significantly enhancing the accessibility of cell-based therapies.This USD financing will accelerate Qrigincell Therapeutics' internationalization and clinical development process, strengthen its technical capabilities in the cell therapy field, and enhance the value of its industrialization pipeline.Dr. Yang Huanfeng, Co-founder and CEO of Qrigincell Therapeutics, stated："Thanks to the investors for their recognition of the company. The company will continue to focus on the global clinical advancement of its core pipeline, in vivo products, and cutting-edge technology R&D. Leveraging its profound technical expertise and current opportunities in policy and market, the company will accelerate the development of clinical-stage products. With more breakthrough cell therapy solutions, it aims to bring new hope of cure to cancer patients worldwide and steadily move towards becoming a global leader in immunotherapy."Mr. Peng Ren, Chairman and General Manager of Beijing Shunxi Private Fund Management Co., Ltd., stated"We believe that cell therapy is an important direction for overcoming solid tumors, and the clinical progress of Oricell Therapeutics' GPC3 CAR-T in treating liver cancer has been very surprising. We highly recognize the team's R&D capabilities and commercial vision, and we look forward to this round of financing helping the company accelerate the global clinical breakthrough of its core products."Mr. Hu Xubo, Managing Partner of Qiming Venture Partners, stated"As an early investor in Qrigincell Therapeutics, we have accompanied and witnessed the company's deep cultivation and steady advancement in the CAR-T field: from autologous CAR-T to secretory CAR-T, to a 3-day rapid production process, and the forward-looking layout of in vivo CAR-T. We have seen the company’s continuous innovation in research and development. We are delighted to be part of a process with the potential to produce globally groundbreaking technologies and products."Source: Oricell Therapeutics
Mastering CAR-T Therapy, Stem Cell Therapy, Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
